Clinical pharmacokinetics of tumor necrosis factor antagonists.

  title={Clinical pharmacokinetics of tumor necrosis factor antagonists.},
  author={Ivan Nestorov},
  journal={The Journal of rheumatology. Supplement},
  • Ivan Nestorov
  • Published 2005 in The Journal of rheumatology. Supplement
Clinical pharmacokinetics of the 3 existing marketed tumor necrosis factor (TNF) antagonists, adalimumab (Abbott Laboratories), etanercept (Amgen, Inc.), and infliximab (Centocor, Inc.) are reviewed. The relevance and potential clinical implications of any differences in their pharmacokinetic properties are outlined. The major therapeutic goal when administering TNF antagonists is to eliminate the surplus of TNF from the circulation and from sites of inflammation. Within the causal chain of… CONTINUE READING
28 Citations
0 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…